BioCryst Pharmaceuticals, Inc. Stock price

Equities

BCRX

US09058V1035

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 09:30:57 2024-03-28 am EDT 5-day change 1st Jan Change
5.22 USD +1.36% Intraday chart for BioCryst Pharmaceuticals, Inc. -5.85% -14.02%
Sales 2024 * 397M Sales 2025 * 486M Capitalization 1.06B
Net income 2024 * -116M Net income 2025 * -50M EV / Sales 2024 * 3.26 x
Net Debt 2024 * 234M Net Debt 2025 * 259M EV / Sales 2025 * 2.72 x
P/E ratio 2024 *
-8.95 x
P/E ratio 2025 *
-18.3 x
Employees 536
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.92%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM
Transcript : BioCryst Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 26, 2024
BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows as Revenue Increases MT
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Posts Q4 Revenue $93.4M, vs. Street Est of $90M MT
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024 CI
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Traders Await Inflation Data This Week DJ
BioCryst Launches Hereditary Angioedema Drug in Italy MT
BioCryst Launches Orladeyo (Berotralstat) in Italy CI
Transcript : BioCryst Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:00 PM
BioCryst Pharmaceuticals Sees FY23, FY24 Orladeyo Sales Topping Prior Forecast; Eyes 2024 Operating Profit MT
BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 CI
BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat) CI
Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023 CI
More news
1 day+2.79%
1 week-5.85%
Current month-8.53%
1 month-12.27%
3 months-16.80%
6 months-31.52%
Current year-14.02%
More quotes
1 week
4.84
Extreme 4.84
5.51
1 month
4.82
Extreme 4.815
5.93
Current year
4.82
Extreme 4.815
7.75
1 year
4.82
Extreme 4.815
9.07
3 years
4.82
Extreme 4.815
19.99
5 years
1.38
Extreme 1.38
19.99
10 years
1.38
Extreme 1.38
19.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 06-12-31
Director of Finance/CFO 44 20-04-01
Director of Finance/CFO 54 10-12-31
Members of the board TitleAgeSince
Director/Board Member 62 20-02-26
Chief Executive Officer 63 06-12-31
Director/Board Member 60 21-07-25
More insiders
Date Price Change Volume
24-03-27 5.15 +2.79% 2 990 374
24-03-26 5.01 +2.04% 3,159,988
24-03-25 4.91 -2.00% 2,828,319
24-03-22 5.01 -8.74% 3,296,041
24-03-21 5.49 +0.37% 2,726,058

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers and commercializes oral, small-molecule medicines. The Company focuses on oral treatments for rare diseases, in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), BCX9930, BCX9250, PERAMIFLU (peramivir injection), galidesivir, and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. BCX9930 is an oral, potent, and selective small molecule inhibitor of Factor D. Galidesivir is a broad-spectrum antiviral that is active against viral families.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
5.15 USD
Average target price
12.2 USD
Spread / Average Target
+136.89%
Consensus
  1. Stock
  2. Equities
  3. Stock BioCryst Pharmaceuticals, Inc. - Nasdaq